NCT05916261View on ClinicalTrials.gov

Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

December 30, 2026

Conditions
Advanced Pancreatic Cancer
Interventions
BIOLOGICAL

Personalized neoantigen tumor vaccine

neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab

Trial Locations (1)

Unknown

RECRUITING

Ruijin-Hainan Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Qionghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER